^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KIF5A (Kinesin Family Member 5A)

    i
    Other names: KIF5A, Kinesin Family Member 5A, NKHC, D12S1889, MY050, Kinesin Heavy Chain Neuron-Specific 1, Neuron-Specific Kinesin Heavy Chain, Kinesin Heavy Chain Isoform 5A, Neuronal Kinesin Heavy Chain, SPG10, Spastic Paraplegia 10 (Autosomal Dominant), Kinesin, Heavy Chain, Neuron-Specific, KIF5A Variant Protein, ALS25, NEIMY, NKHC1
    Associations

    News

    Trials
    5ms
    Kinesin superfamily proteins in cancer: unveiling their role in chemotherapy. (PubMed, Int Immunopharmacol)
    KIF5A, KIF11, and KIF20A are consistently involved in resistance to paclitaxel and docetaxel in breast, lung, and prostate cancers, while KIF14 overexpression is a prognostic marker for poor outcomes in paclitaxel-treated triple-negative breast and cervical cancer. KIF14 and KIF23 in HCC enhance sorafenib and cisplatin resistance, while suppression of KIF5B or KIF20A increases sensitivity to oxaliplatin in colorectal cancer...Present approaches-small-molecule inhibitors, microRNA modulation, and KIF20A peptide vaccines-are hopeful but are beset by issues of toxicity and specificity. Overall, KIFs are context-dependent regulators of chemoresistance and are multifunctional but promising precision oncology targets.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • KIF5B (Kinesin Family Member 5B) • KIF11 (Kinesin Family Member 11) • KIF20A (Kinesin Family Member 20A) • KIF23 (Kinesin Family Member 23) • KIF5A (Kinesin Family Member 5A)
    |
    ALK fusion
    |
    cisplatin • sorafenib • paclitaxel • docetaxel • oxaliplatin
    6ms
    SNHG16-loaded extracellular vesicles from hypoxic NSCLC cells drive M2 macrophage polarization to enhance cancer aggressiveness. (PubMed, Mol Immunol)
    Rescue experiments confirmed that SNHG16-EVs induced NSCLC progression and M2 polarization of THP-1 cells were all reversed by overexpressing miR-132-3p and silencing KIF5A. Collectively, hypoxia-stimulated NSCLC cells transferred SNHG16-containing EVs to promote cancer aggressiveness and M2-polarized macrophages in NSCLC through modulating the downstream miR-132-3p/KIF5A axis, and this study verified that targeting SNHG16-EVs may be a novel strategy to hamper NSCLC progression via modulating TME.
    Journal
    |
    IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • MIR132 (MicroRNA 132) • SNHG16 (Small Nucleolar RNA Host Gene 16) • KIF5A (Kinesin Family Member 5A)
    9ms
    RETRACTION: KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo. (PubMed, Dis Markers)
    [This retracts the article DOI: 10.1155/2019/4824902.].
    Preclinical • Journal
    |
    KIF5A (Kinesin Family Member 5A)
    9ms
    Unveiling GBE1 as a hypoxia-related prognostic gene with significant impact on immune cell infiltration in HER2-enriched breast cancer. (PubMed, Discov Oncol)
    Notably, GBE1 emerged as a significant gene, impacting both patient survival and the most immune cell infiltration. Hence, further studies are warranted to elucidate its precise mechanisms and explore its potential as a therapeutic target in cancer immunotherapy.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BNIP3L (BCL2 Interacting Protein 3 Like) • IGFBP3 (Insulin-like growth factor binding protein 3) • KIF5A (Kinesin Family Member 5A)
    |
    HER-2 expression
    1year
    Regulatory Role of Long Noncoding RNAs LINC00449 in Hepatocellular Carcinoma Mechanism and Prognosis Via Sponge miR-329-3p/KIF5A Axis. (PubMed, Turk J Gastroenterol)
    Moreover, LINC00449 targeting the miR-329-3p/KIF5A axis influences the progression of HCC. LINC00449 may become a biomarker for the prognosis of HCC, and the LINC00449/miR-329-3p/KIF5A regulatory network mediates the deterioration of HCC.
    Journal
    |
    KIF5A (Kinesin Family Member 5A)
    over1year
    Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma. (PubMed, Clin Respir J)
    This project uncovered that the small molecular drug Ergotamine targets and inhibits the expression of KIF5A. Downregulated KIF5A can enhance the anoikis of LUAD. Our results supported the inhibition of KIF5A as an attractive therapeutic strategy for LUAD. This finding provides a new innovative pathway for the treatment of LUAD and offers a strong theoretical basis for the development of therapeutic drugs targeting KIF5A.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CAV1 (Caveolin 1) • KIF5A (Kinesin Family Member 5A)
    over1year
    NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors. (PubMed, Acta Neuropathol Commun)
    Four patients received adjuvant TRK inhibitor therapy (larotrectinib, repotrectinib, or entrectinib), among which three also received chemotherapy (n = 2) or proton therapy (n = 1). This patient had previously experienced relapse after the initial surgery and underwent autologous peripheral blood stem cell therapy with carboplatin/thiotepa and proton therapy. Conclusions Our study clarifies the distinct differences in the pathology and TRK inhibitor response between LGG and HGG with NTRK fusions.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • MDM4 (The mouse double minute 4) • TPM3 (Tropomyosin 3) • TFG (Trafficking From ER To Golgi Regulator) • FKBP15 (FKBP Prolyl Isomerase 15) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like) • GKAP1 (G Kinase Anchoring Protein 1) • KIF5A (Kinesin Family Member 5A)
    |
    carboplatin • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • thiotepa
    over1year
    FOXP3 targets KIF5A to increase lactate production and promote docetaxel resistance in lung adenocarcinoma. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Our findings reveal that FOXP3 increases DTX resistance in LUAD cells by enhancing lactate production through the upregulation of KIF5A level. In conclusion, our study provides a novel treatment target for improving chemosensitivity in LUAD.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • FOXP3 (Forkhead Box P3) • KIF5A (Kinesin Family Member 5A)
    |
    docetaxel